What is Surrozen?
Surrozen is a biotechnology firm dedicated to the discovery and development of drug candidates that selectively modulate the Wnt pathway. By engineering tissue-specific antibodies, the company aims to activate the body's natural biological repair processes. This innovative approach holds transformative potential across a diverse range of therapeutic areas, including inflammatory bowel disease, hepatitis, ophthalmology, hearing loss, and various pulmonary and neurological disorders. Through its unique platform, Surrozen is effectively bridging the gap between fundamental biological research and clinical application, targeting diseases that have historically lacked effective regenerative treatments.
How much funding has Surrozen raised?
Surrozen has raised a total of $308M across 4 funding rounds:
Series A
$33M
Series B
$50M
Series C
$50M
Share Placement
$175M
Series A (2017): $33M with participation from The Column Group
Series B (2019): $50M led by The Column Group
Series C (2020): $50M supported by Hartford Healthcare Trust, The Column Group, and Horizons Ventures
Share Placement (2025): $175M, investors not publicly disclosed
Key Investors in Surrozen
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, employing an edge-to-edge investment model that nurtures platforms from inception to exit.
Horizons Ventures
Horizons Ventures is a global investment firm that partners with visionary entrepreneurs to transform early-stage startups into successful, market-leading companies through active involvement and equity financing.
Hartford Healthcare Trust
An institutional investor providing strategic capital to support the growth and development of innovative healthcare and biotechnology enterprises.
What's next for Surrozen?
With the successful completion of this major strategic investment, Surrozen is well-positioned to accelerate its clinical development programs and expand its therapeutic reach. The capital will likely be deployed to advance its lead candidates through critical trial phases, further validating the efficacy of its Wnt-modulating platform. As the company transitions into a more mature stage of development, the focus will shift toward optimizing manufacturing processes and exploring potential strategic partnerships to broaden the commercial viability of its pipeline. Investors and stakeholders will be closely monitoring the upcoming data readouts, which are expected to serve as key catalysts for the company's long-term valuation and market impact in the biotechnology sector.
See full Surrozen company page
